Virscio Deploys Proscia Software To Improve Efficiency Of Drug Research And Development
Proscia: Cloud-based digital pathology platform helps CRO deliver more informed preclinical studies
NEW HAVEN, CONN. and PHILADELPHIA – April 24, 2023 – Proscia®, a leading provider of digital and computational pathology solutions, today announced that Virscio, a leading provider of translational research and development services, has deployed Concentriq® for Research. The contract research organization (CRO) is leveraging Proscia’s flagship software platform to provide faster, more informed drug safety insights, helping its sponsors to improve research and development (R&D) efficiency.
90% of drug candidates fail during clinical trials.[1] This negatively impacts R&D efficiency, as measured by the number of new drugs approved relative to investment. Effective preclinical development hinges on accurate and high throughput evaluation of large volumes of pathology data to define the safety of a candidate before it can move on to human clinical trials. As such, Virscio recognized that optimizing its pathology operations by adopting Concentriq for Research would enable its sponsors to more rapidly and confidently advance lead programs and get therapeutic breakthroughs to patients sooner.
Concentriq is trusted by 14 of the top 20 pharmaceutical companies and leading CROs to drive quality and productivity gains across the R&D value chain. Virscio is leveraging the scalable, cloud-based platform to unify its teams and data across Good Laboratory Practice (GLP) and non-regulated studies, streamlining collaboration among its distributed scientists, sponsors, and external collaborators. The platform also offers world-class interoperability with leading image analysis and artificial intelligence (AI) applications, allowing Virscio’s scientists to unlock new insights that further inform decision making.
“Translating concept to clinical success requires innovative technology, and we’ve found this in Concentriq for Research,” said Matthew Lawrence, M.D., Ph.D., Virscio’s Chief Executive Officer. “The platform enables us to see through our transformative approach to preclinical development and create added value for our teams and sponsors.”
With today’s news, Virscio joins other life sciences organizations on the forefront of digital pathology adoption. Concentriq for Research augments its integrated in-life and histology capabilities and unparalleled access to highly translational in vivo models that truly predict risk and response to meet the expanding demands of the biotechnology and pharmaceutical companies it serves. In turn, Virscio is further positioned to overcome lengthening drug development timelines and reduce development costs; the average drug takes 10 to 15 years and costs $2.6 billion to bring to market.[2]
“We are excited to welcome Virscio to the growing roster of organizations turning to Concentriq for Research to accelerate therapeutic innovation,” said David West, Proscia’s Chief Executive Officer. “Virscio is driving forward a new era of preclinical development, and we look forward to seeing the impact of digital pathology in addressing the critical challenge of R&D efficiency.”
About Virscio
Virscio is a specialty translational research organization developing and providing innovative preclinical research services, highly translational in vivo models, and related preclinical and histopathology services to meet the preclinical, translational, and regulatory research needs of the life sciences, biotechnology, and pharmaceutical industries. Virscio specializes in non-GLP and GLP in vivo study design, execution, and sample, data, and image analysis to enable rapid translation of preclinical therapeutic candidates from early proof of concept to IND-enabling studies, leveraging unique and significant access to nonhuman primates and integrated therapeutic domain expertise and capabilities.
For more information, please visit virscio.com.
About Proscia
Proscia is a software company that is accelerating pathology’s digital transformation to change the way we understand diseases like cancer. Its Concentriq digital pathology platform and powerful AI applications are advancing the 150-year-old standard of research and diagnosis towards a data-driven discipline, unlocking new insights that accelerate R&D, improve patient outcomes, and fulfill the promise of precision care. Leading diagnostic laboratories and 14 of the top 20 pharmaceutical companies rely on Proscia’s software each day. For more information, visit proscia.com.
[1] Sun, D. et al (2022, July). Why 90% of clinical drug development fails and how to improve it? Acta Pharmaceutica Sinica B. 12 (7). Retrieved April 19, 2023, from https://doi.org/10.1016/j.apsb.2022.02.002
[2] Pharmaceutical Researchers and Manufacturers of America. (2021, September 30). Research & Development Policy Framework. PhRMA Org. Retrieved April 19, 2023, from https://phrma.org/policy-issues/Research-and-Development-Policy-Framework
SOURCE: Proscia
